63 results about "During menopause" patented technology

The invention belongs to the field of biological medicines, and particularly discloses a mesenchymal stem cell and cytokine preparation having treatment effects on premature ovarian failures and perimenopausal syndromes, and a preparing method for the preparation. The preparation is composed of umbilical cord or placenta mesenchymal stem cells and cytokines, as well as hyaluronate which is used for bearing the umbilical cord or placenta mesenchymal stem cells and cytokines and has the slow-release and anti-inflammatory effects; and the preparation is injected into a part of the endometrium and ovary in a targeted manner to be slowly released and absorbed. The curative effect of repairing the ovary and endometrium can be achieved, functional ovulation can be promoted, the premature ovarian failures can be treated, and the various perimenopausal syndromes can be remitted. Compared with an existing intravenous re-transfusion and intervention path, untoward effects of intravenous transfusion are avoided through the preparation and a using method of the preparation, abdomen and local wounds caused by interventional treatment are avoided, and side effects and hurts caused by treatment to a patient can be effectively prevented, so that the preparation is safer and more effective, is high in practicability and easy to popularize, and has the huge application value.

The invention relates to a Chinese medicament health product for supplementing female hormone for women during menopause. The Chinese medicament health product comprises the oral medication raw materials of epimedium herb, radix paeoniae alba, raspberry, motherwort, angelica sinensis, fructus corni, yerbadetajo herb, polygala, wolfberry fruit, placenta hominis, fructus ligustri lucidi, radix polygoni multiflori, dodder, broomrape, semen boitae, rhizoma anemarrhenae, mulberries, rhizoma curculiginis, prepared rhizome of rehmannia, semen zizyphi spinosae, rhizoma cyperi, fructus tritici levis, tuckahoe, Chinese dage and flos albiziae, and external-use raw materials of common cnidium fruit, rhizoma ligustici wallichii, epimedium herb, caulis spatholobi, cortex albiziae, phellodendron bark, red sage root, tuber fleeceflower stem, mother-of-pearl, red raspberry and herba leonuri. The Chinese medicament health product can stimulate adrenal hyperblastosis, improve the level of female hormone, obviously adjust the vegetative nerve function, reduce endocrine disequilibrium, improve psychataxia and maintain homergy, and all the medicaments are compatible with one another to achieve effects of warming the kidney, benefiting yin, and regulating and tonifying yin and yang.

The present invention is directed to a method of treating, preventing, or reducing the risk of bone deterioration or osteoporosis in a peri- or post-menopausal female subject. The method involves selecting a peri- or post-menopausal female subject in need of treating, preventing, or reducing the risk of bone deterioration or osteoporosis and administering hepcidin to the selected subject under conditions effective to treat, prevent, or reduce the risk of bone deterioration or osteoporosis.

The invention discloses an active part of Sambucus williamsii Hance with the effect of reducing bone mass loss after menopause. The active part has definite chemical components and mainly comprises seven compounds: vanillic acid, coniferol, levo erythro form guaiacyl glycerol-beta-O-4'-coniferyl alcohol ether, dextro threo form-1-(4-hydroxy-3-methoxyphenyl)-2-[-4-(3-hydroxypropyl)-2-hydroxyphenoxy]-1,3-propanediol, dextro threo form guaiacyl glycerol-beta-O-4'-coniferyl alcohol ether, coniferyl alcohol dehydrogenase and dihydro-coniferyl alcohol dehydrogenase. The active part can remarkably reduce the bone loss of ovariectomized mice, increase bone density of thighbone and shinbone, increase bone volume, does not increase the weight of uterus, and is a component for safely and effectivelyrelieving and improving various symptoms of the bone-related diseases of the menopausal women. The invention has the advantages of providing the active part of the Sambucus williamsii Hance which canbe used for preparing a medicament, food or a food additive for preventing and treating the bone-related diseases after menopause.

The invention discloses an application of catalpol in preparing ovarian aging resisting medicaments. The catalpol can treat various ovarian aging diseases, and particularly has obvious effects on polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovarian failure or menopause syndrome and the like. According to the application, the catalpol is prepared into oral medicaments, transdermal medicaments or injections for treating ovarian failure diseases.

Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating perimenopausal or menopausal patients, such as patients suffering from, experiencing, exhibiting and/or having one or more symptoms of anxiety or depression, are also disclosed.

Disclosed is a medicinal composition and method of use comprising topiramate for treating hot flashes and excessive sweating known as vasomotor symptoms related to perimenopausal or menopausal symptoms and in a still further embodiment of the invention topiramate and the medicine for treating menopause and perimenopause are provided in a kit or in unit dosage form, e.g., tablet or capsule. As a further embodiment of this invention, topiramate may be administered along with a medicament use to treat hot flashes and excessive sweating related to perimenopausal or menopausal symptoms.

The invention provides an extract for truffles in a hydrophilic solvent. The exact serves as an active ingredient for and is used in the preparation of drugs for preventing and treating women's hormonal imbalance, perimenopause syndrome, senile urethritis and sleep disorder, or food or health care food for improving the related functions.

The invention discloses a medicinal composition for treating vaginal dryness. The composition comprises 50-80 wt% of Oviductus Ranae, and 20-50 wt% of Chinese herbal powder. The medicinal composition has effects in invigorating kidney and vital essence, nourishing Yin and blood, promoting qi circulation to remove stagnation; and can be used for treating symptoms such as vaginal dryness, sexual pain and sexual hypoactivity due to perimenopause or ovary dysfunction. The composition is simple in formula and production, and effective in curative effect, is prepared from pure Chinese medicinal materials, and has no toxic and side effects.

A product for treating conditions and/or symptoms associated with women health is described, which product comprises at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene, carrier, optionally at least three secondary terpenes, and optionally at least one phytoestrogen; wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said product is about 0.1 to about 1.0. Also described is the product wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight/weight ratio in said compositions is about 0.05 to about 1.0, forming a terpene-enriched product. Also described are uses of the product for treating conditions and/or symptoms associated with perimenopause, menopause, female urogenital or reproductive system infections and/or disorders, menstrual cycle, hormonal deficiency and/or hormonal imbalance.

The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-memopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain. The present disclosure is also directed to method and/or compositions for reducing elasticity and/or decreasing mechano-transduction on the genome of breast cells. The present disclosure is also directed to methods and/or compositions for stabilizing and/or increasing the levels of androgen receptor expression in breast tissue.

The invention relates to at least one probiotic strain chosen from Lactobacillus paracasei 8700:2 (DSM 13434) and/or at least one probiotic strain of Lactobacillus piantarum, for use in the treatment and/or prevention of trabecular bone loss, in a mammal, preferably in anon-rodent mammal, more preferably in a human, most preferably in a peri-menopausal woman, post-menopausal woman or a woman six years or less after onset of menopause.

The invention provides a compound preparation, which is applied to prevention and/or treatment of female perimenopausal urogenital syndrome and comprises the following main components: epidermal growth factors, sea buckthorn seed oil and glycerol. The invention further provides novel application of the compound preparation, namely application of the compound preparation in prevention and/or treatment of the female perimenopausal urogenital syndrome and application of the compound preparation in products of the female perimenopausal urogenital syndrome. Application in preventing and/or treating female vaginal atrophy, maintaining the state of sexual organs and in products thereof; the invention also relates to an application in prevention and/or treatment of urination disorders such as abnormal urination function, frequent urination, urgent urination and increased nocturnal urination in the perimenopausal period of women and an application in products thereof, and an application in improvement of sex hormone level in the perimenopausal period of women, regulation and recovery of disordered menstrual cycle of women and an application in products thereof. The application provides a basis for preventing and treating the perimenopausal urogenital syndrome by directly utilizing the compound preparation.

The invention discloses an application of fagomine in preparation of an anti-ovarian senescence drug. The fagomine has a remarkable effect on treating various ovarian recession diseases such as polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovarian failure or menopausal syndrome by up-regulating the protein levels of c-fos mRNA and expression products thereof. The fagomineis prepared into oral administration, transdermal administration or injection administration for treating ovarian recession diseases.

The present invention provides methods to reduce the number and severity of hot flashes utilizing tocotrienols. In particular, symptoms of perimenopause and menopause may be treated using the present methods. The present invention also provides methods to increase tissue concentrations of tocotrienols.

Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or moreconditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility.

This invention relates to methods and pharmaceutical compositions for providing hormone replacement therapy in perimenopausal, menopausal, and postmenopausal women through the continuous administration of combinations of conjugated estrogens and trimegestone.